MIGRAINE TREATMENT WITH NICARDIPINE

被引：11

作者：

LEANDRI, M

RIGARDO, S

SCHIZZI, R

PARODI, CI

机构：

[1] Department of Neurology, University of Genoa, 16132 Genoa, via De Toni

[2] Department of Neurology, Ospedale Galliera, 16128 Genoa, Via Mura delle Cappuccine

来源：

CEPHALALGIA | 1990年 / 10卷 / 03期

关键词：

Calcium entry blockers; migraine; nicardipine;

D O I：

10.1046/j.1468-2982.1990.1003111.x

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

A novel calcium entry blocker, nicardipine, has been tested using a dosage of 20 mg twice a day against placebo on 30 patients suffering from migraine without aura, according to a double-blind, cross-over design; overall duration of the study was four months (two with nicardipine and two with placebo). Migraine parameters such as monthly frequency, mean intensity and mean duration of attacks were monitored. Two indexes were also calculated: index A (monthly frequency x mean intensity) and index B (monthly frequency x mean intensity x mean duration). All the parameters considered and the two indexes showed a marked and significant improvement after nicardipine treatment in comparison to both placebo and pre-study scores. Detailed analysis of the cross-over results showed that improvement obtained with nicardipine lasted some time after the drug was discontinued. Nicardipine did not alter the blood and attention tests performed and caused few side effects. © 1990, International Headache Society. All rights reserved.

引用

页码：111 / 116

页数：6

共 27 条

[1]

Yamamoto M., Meyer J.S., Hemicranial disorder of vasomotor adrenoceptors in migraine and cluster headache, Headache, 20, pp. 321-335, (1980)

[2]

Amery W.K., Wauquier A., Van Nueten J.M., De Clerch F., Van Reempts J.V., Janssen P.A.J., The anti-migrainous pharmacology of flunarizine (r-14--950), a calcium antagonist, Drugs Exptl Clin Res, 7, pp. 1-10, (1981)

[3]

Meyer J.S., Hardembeg J., Clinical effectiveness of calcium entry blockers in prophylactic treatment of migraine and cluster headaches, Headache, 23, pp. 266-273, (1983)

[4]

Peroutka S.J., The pharmacology of calcium channel antagonists: a novel class of anti-migraine agents?, Headache, 23, pp. 278-283, (1983)

[5]

Peroutka S.J., Banghart S.B., Allen G.S., Relative potency and selectivity of calcium antagonists used in the treatment of migraine, Headache, 24, pp. 55-59, (1984)

[6]

Havanka-Kanniainen H., Hokkanen E., Myllyla V.V., Efficacy of nimodipine in the prophylaxis of migraine, Cephalalgia, 5, pp. 39-43, (1985)

[7]

Jensen K., Tfelt-Hansen P., Lauritzen M., Olesen J., Clinical trial of nimodipine for single attacks of classic migraine, Cephalalgia, 5, pp. 125-131, (1985)

[8]

Mendenopoulos G., Manafi T., Logothetis I., Bostantjopoulou S., Flunarizine in the prevention of classical migraine: a placebo controlled evaluation, Cephalalgia, 5, pp. 31-37, (1985)

[9]

Meyer S.J., Nance M., Walker M., Zetusky W.J., Dowell R.E., Migraine and cluster headache treatment with calcium antagonists supports a vascular pathogenesis, Headache, 25, pp. 358-367, (1985)

[10]

Solomon G.D., Comparative efficacy of calcium antagonist drugs in the prophylaxis of migraine, Headache, 25, pp. 368-371, (1985)

← 1 2 3 →